The Synergy of Gene Targeting Drug Icaritin Soft Capsule with Immunomodulator and TACE Brings New Hope for Drug Combination in Patients with Advanced Liver Cancer: A Case Report and Literature Review

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2023 Jul 24

PMID 37485037

Authors

Xiaoxia Tang

Yizhuo Zhang

Xinyu Dong

Guixing Jiang

Defei Hong

Xiaolong Liu

Affiliations

Soon will be listed here.

Abstract

At present, the average five-year survival rate of liver cancer in China is only 12.1%. The reason for this association lies in the diagnosis at its middle or/and advanced stage of liver cancer for lacking special clinical symptoms in almost 70% of patients without the chance of effective surgical resection. Epidemiological studies have shown that there are only 30% of patients with an initial diagnosis of liver cancer have the opportunity to undergo radical surgery. Therefore, systematic and comprehensive treatment would play an important role in liver cancer treatment at its middle or/and advanced stage, and the related therapeutic schedule still needs further improvement and optimization. We applied a gene-targeted drug of Icaritin soft capsule in the treatment of a liver cancer patient at its advanced stage. And the level of AFP was found to decrease to 6.4ng/mL from 10.86ng/mL; meanwhile, MRI showed that the primary tumor significantly reduced in size, with shrinking of the hepatogastric space, hepatic aortic side, and renal artery side lymph nodes. After treatment with TACE and Icaritin, the patient had no discomfort and no longer experienced abdominal pain and bloating and gained three kilograms of weight. The therapeutic effect of Icaritin-targeted drugs was completely demonstrated during the later treatment follow-up. That is to say, the multiple anti-tumor characteristics of Icaritin with good safety were fully displayed in this case, and it can be used in combination with other drugs to treat hepatocellular carcinoma in the clinical setting. The results show that Icaritin can put some effects on the combined treatment of patients with liver cancer.

Citing Articles

COE targets EphA2 to inhibit vasculogenic mimicry formation induced by hypoxia in hepatocellular carcinoma.

Chen J, Dai S, Wu S, Wu M, Yu K, Liu J Front Pharmacol. 2024; 15:1421470.

PMID: 39050762 PMC: 11266089. DOI: 10.3389/fphar.2024.1421470.

Advancements in the Biotransformation and Biosynthesis of the Primary Active Flavonoids Derived from .

Zhang X, Tang B, Wen S, Wang Y, Pan C, Qu L Molecules. 2023; 28(20).

PMID: 37894651 PMC: 10609448. DOI: 10.3390/molecules28207173.

References

Jin L, Miao J, Liu Y, Li X, Jie Y, Niu Q . Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells. Biomed Pharmacother. 2016; 85:287-295. DOI: 10.1016/j.biopha.2016.11.023. View

Kudo M . A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer. 2019; 8(5):299-311. PMC: 6872999. DOI: 10.1159/000502905. View

Xu B, Jiang C, Han H, Liu H, Tang M, Liu L . Icaritin inhibits the invasion and epithelial-to-mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF-1α signalling. Clin Exp Pharmacol Physiol. 2015; 42(12):1296-307. DOI: 10.1111/1440-1681.12488. View

Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y . IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. Onco Targets Ther. 2020; 13:9721-9730. PMC: 7533247. DOI: 10.2147/OTT.S262089. View

Wang S, Wang Q, Wang H, Qin C, Cui X, Li L . Induction of ROS and DNA damage-dependent senescence by icaritin contributes to its antitumor activity in hepatocellular carcinoma cells. Pharm Biol. 2019; 57(1):424-431. PMC: 8871611. DOI: 10.1080/13880209.2019.1628073. View

Zhao H, Guo Y, Li S, Han R, Ying J, Zhu H . A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget. 2015; 6(31):31927-43. PMC: 4741651. DOI: 10.18632/oncotarget.5578. View

Ryder S . Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003; 52 Suppl 3:iii1-8. PMC: 1867754. DOI: 10.1136/gut.52.suppl_3.iii1. View

McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View

Tao H, Liu M, Wang Y, Luo S, Xu Y, Ye B . Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation. Front Immunol. 2021; 12:609295. PMC: 7952329. DOI: 10.3389/fimmu.2021.609295. View

10.

Zhang C, Xu H, Sui X, Chen L, Chen B, Lv H . Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime. Mol Ther Oncolytics. 2022; 25:288-304. PMC: 9127125. DOI: 10.1016/j.omto.2022.04.012. View

11.

Zhu S, Wang Z, Li Z, Peng H, Luo Y, Deng M . Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget. 2015; 6(12):10460-72. PMC: 4496367. DOI: 10.18632/oncotarget.3399. View

12.

Anwanwan D, Singh S, Singh S, Saikam V, Singh R . Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188314. PMC: 6981221. DOI: 10.1016/j.bbcan.2019.188314. View

13.

Yang H, Kim J, Lee J, Lee B, Park K, Shim K . Celastrol isolated from Tripterygium regelii induces apoptosis through both caspase-dependent and -independent pathways in human breast cancer cells. Food Chem Toxicol. 2010; 49(2):527-32. DOI: 10.1016/j.fct.2010.11.044. View

14.

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag C, Vignat J . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6):1598-1606. PMC: 9670241. DOI: 10.1016/j.jhep.2022.08.021. View

15.

Li H, Liu Y, Jiang W, Xue J, Cheng Y, Wang J . Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma. BMC Cancer. 2021; 21(1):318. PMC: 7992931. DOI: 10.1186/s12885-021-08043-9. View

16.

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M . Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020; 18(1):59. PMC: 7140346. DOI: 10.1186/s12964-020-0530-4. View

17.

Dai Z, Wang X, Peng R, Zhang B, Han Q, Lin J . Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2021; 524:161-171. DOI: 10.1016/j.canlet.2021.10.024. View

18.

Li Q, Sun J, Cao Y, Liu B, Zhao Z, Hu L . Icaritin inhibited cigarette smoke extract-induced CD8 T cell chemotaxis enhancement by targeting the CXCL10/CXCR3 axis and TGF-β/Smad2 signaling. Phytomedicine. 2022; 96:153907. DOI: 10.1016/j.phymed.2021.153907. View

19.

Sun L, Chen W, Qu L, Wu J, Si J . Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P‑glycoprotein expression. Mol Med Rep. 2013; 8(6):1883-7. DOI: 10.3892/mmr.2013.1742. View

20.

Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X . Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2019; 30(6):571-579. PMC: 6328503. DOI: 10.21147/j.issn.1000-9604.2018.06.01. View